Antiplatelet Therapy in Thrombocytopenia

Introduction to Antiplatelet Therapy

The European Society of Cardiology recommends continuing antiplatelet therapy in patients with thrombocytopenia and high thrombotic risk when platelet counts are ≥50,000/μL, but avoiding adding antiplatelet agents to anticoagulation in patients with documented or suspected heparin-induced thrombocytopenia (HIT) 1, 2, 3

The American Society of Hematology suggests that aspirin 75-100 mg daily or clopidogrel 75 mg daily can be safely administered at a platelet count threshold of ≥50,000/μL 3
No dose adjustment or discontinuation of antiplatelet therapy is required based solely on platelet count at this level, according to the American College of Cardiology 3
For patients with a platelet count between 30,000-50,000/μL, the American Heart Association recommends continuing aspirin if high thrombotic risk exists, but monitoring closely and treating underlying thrombocytopenia 3
The European Society of Cardiology advises against dual antiplatelet therapy in this range, as it substantially increases bleeding risk, particularly in thrombocytopenia 3

The European Society of Cardiology recommends discontinuing all heparin products immediately when HIT is documented or strongly suspected, and initiating non-heparin anticoagulant instead of adding antiplatelet therapy 1, 5, 6, 2, 7
The American Society of Hematology suggests that argatroban or bivalirudin are preferred in critically ill patients or those with increased bleeding risk due to shorter duration of effect, while fondaparinux or DOACs are reasonable options in clinically stable patients at average bleeding risk 7

The American College of Cardiology advises against discontinuing aspirin based solely on platelet count of 100,000/μL or higher, as this significantly increases stroke risk without meaningful reduction in bleeding risk 3
The European Society of Cardiology recommends avoiding NSAIDs, as they antagonize aspirin's antiplatelet effect and increase bleeding risk, and discontinuing GPIIb/IIIa inhibitors immediately if thrombocytopenia <100,000/μL develops during treatment 3, 1, 5

The American Society of Hematology recommends monitoring platelet counts every 2-3 days from day 4 to day 14 in patients receiving heparin with >1% HIT risk, and monitoring hemoglobin/hematocrit daily to detect occult bleeding when using antiplatelet therapy with thrombocytopenia 6, 4
The European Society of Cardiology suggests weekly platelet count monitoring for at least 2 weeks following any treatment changes, and specific platelet count thresholds for procedures such as lumbar puncture (≥40,000/μL), major surgery (≥50,000/μL), and neurosurgery (≥100,000/μL) 3